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This document is a critical synopsis of prior work by Michael Dwyer, submitted 
in support of a PhD by published work. The selected work is focused on the 
application of quantitative magnetic resonance imaging (MRI) analysis 
techniques to the study of multiple sclerosis (MS). 
MS is a debilitating disease with a multi-factorial pathology, progression, and 
clinical presentation. Its most salient feature is focal inflammatory lesions, but it 
also includes significant parenchymal atrophy and microstructural damage. As a 
powerful tool for in vivo investigation of tissue properties, MRI can provide 
important clinical and scientific information regarding these various aspects of 
the disease, but precise, accurate quantitative analysis techniques are needed 
to detect subtle changes and to cope with the vast amount of data produced in 
an MRI session. 
To address this, eight new techniques were developed by Michael Dwyer and 
his co-workers to better elucidate focal, atrophic, and occult/―invisible‖ 
pathology. These included: a method to better evaluate errors in lesion 
identification; a method to quantify differences in lesion distribution between 
scanner strengths; a method to measure optic nerve atrophy; a more precise 
method to quantify tissue-specific atrophy; a method sensitive to dynamic 
myelin changes; and a method to quantify iron in specific brain structures. 
Taken together, these new techniques are complementary and improve the 
ability of clinicians and researchers to reliably assess various key elements of 
MS pathology in vivo. 
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Chapter 1 – Introduction 
1.1 Purpose 
This document is a synopsis of the published work of Michael Dwyer (hereafter 
referred to as the author), which is herewith submitted for a PhD by published 
work. 
1.2 Selected publications 
The body of published work submitted for this PhD is itemized in Table 1, which 
comprises eleven journal papers and one conference proceeding. Copies of 
these publications are included in Appendix B. They have been selected 
because they represent both a significant contribution to the scientific 
knowledge base and either primary or substantial involvement from the author. 
Additional supporting material, which comprises the eleven journal papers 
itemized in Table 2, is included in Appendix C.  
Table 1. Publications submitted for inclusion in the PhD 
Ref. 
No. 
Publication Status
*
 
1 Semi-automatic brain region extraction (SABRE) reveals superior 
cortical and deep gray matter atrophy in MS. Carone DA, Benedict RH, 
Dwyer MG, Cookfair DL, Srinivasaraghavan B, Tjoa CW, Zivadinov R. 
Neuroimage. 2006 Jan 15;29(2):505-14. Epub 2005 Oct 5. 
RP*** 
2 
Ref. 
No. 
Publication Status
*
 
2 Effect of MRI coregistration on serial short-term brain volume changes 
in multiple sclerosis. Fritz DA, Dwyer MG, Bagnato F, Watts KL, Bratina A, 
Zorzon M, Durastanti V, Locatelli L, Millefiorini E, Zivadinov R. Neurol Res. 
2006 Apr;28(3):275-9. 
RP*** 
3 Neocortical atrophy, third ventricular width, and cognitive dysfunction 
in multiple sclerosis. Benedict RH, Bruce JM, Dwyer MG, Abdelrahman N, 
Hussein S, Weinstock-Guttman B, Garg N, Munschauer F, Zivadinov R. Arch 
Neurol. 2006 Sep;63(9):1301-6. 
RP*** 
4 Quantitative diffusion weighted imaging measures in patients with 
multiple sclerosis. Tavazzi E, Dwyer MG, Weinstock-Guttman B, Lema J, 
Bastianello S, Bergamaschi R, Cosi V, Benedict RH, Munschauer FE 3rd, 
Zivadinov R. Neuroimage. 2007 Jul 1;36(3):746-54. Epub 2007 Apr 10. 
RP*** 
5 Application of hidden Markov random field approach for quantification 
of perfusion/diffusion mismatch in acute ischemic stroke. Dwyer MG, 
Bergsland N, Saluste E, Sharma J, Jaisani Z, Durfee J, Abdelrahman N, 
Minagar A, Hoque R, Munschauer FE 3rd, Zivadinov R. Neurol Res. 2008 
Oct;30(8):827-34. doi: 10.1179/174313208X340987. 
RP** 
6 A sensitive, noise-resistant method for identifying focal demyelination 
and remyelination in patients with multiple sclerosis via voxel-wise 
changes in magnetization transfer ratio. Dwyer MG, Bergsland N, Hussein 
S, Durfee JE, Wack DS, Zivadinov R. J Neurol Sci. 2009 Jul 15;282(1-2):86-
95. doi: 10.1016/j.jns.2009.03.016. Epub 2009 Apr 22. 
RP** 
7 Relationship of optic nerve and brain conventional and non-
conventional MRI measures and retinal nerve fiber layer thickness, as 
assessed by OCT and GDx: a pilot study. Frohman EM, Dwyer MG, 
Frohman T, Cox JL, Salter A, Greenberg BM, Hussein S, Conger A, 
Calabresi P, Balcer LJ, Zivadinov R. J Neurol Sci. 2009 Jul 15;282(1-2):96-
105. doi: 10.1016/j.jns.2009.04.010. Epub 2009 May 12. 
RP*** 
8 Signal abnormalities on 1.5 and 3 Tesla brain MRI in multiple sclerosis 
patients and healthy controls. A morphological and spatial quantitative 
comparison study. Di Perri C, Dwyer MG, Wack DS, Cox JL, Hashmi K, 
Saluste E, Hussein S, Schirda C, Stosic M, Durfee J, Poloni GU, Nayyar N, 
Bergamaschi R, Zivadinov R. Neuroimage. 2009 Oct 1;47(4):1352-62. doi: 
10.1016/j.neuroimage.2009.04.019. Epub 2009 Apr 14. 
RP*** 
9 Abnormal subcortical deep-gray matter susceptibility-weighted imaging 
filtered phase measurements in patients with multiple sclerosis: a case-
control study. Zivadinov R, Heininen-Brown M, Schirda CV, Poloni GU, 
Bergsland N, Magnano CR, Durfee J, Kennedy C, Carl E, Hagemeier J, 
Benedict RH, Weinstock-Guttman B, Dwyer MG. Neuroimage. 2012 Jan 
2;59(1):331-9. doi: 10.1016/j.neuroimage.2011.07.045. Epub 2011 Jul 27. 
RP*** 
10 Improved assessment of multiple sclerosis lesion segmentation 
agreement via detection and outline error estimates. Wack DS, Dwyer 
MG, Bergsland N, Di Perri C, Ranza L, Hussein S, Ramasamy D, Poloni G, 
Zivadinov R. BMC Med Imaging. 2012 Jul 19;12:17. doi: 10.1186/1471-2342-
12-17. 
RP*** 
11 Improved longitudinal gray matter atrophy assessment via a 
combination of SIENA and a 4-dimensional hidden Markov random field 
model. Dwyer MG, Bergsland N, Zivadinov R. 28th European Committee for 
Treatment and Research in Multiple Sclerosis, Lyon, France, October 10-13, 
2012:P840. 
P** 
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*Status: P = available in the public domain; R = refereed journal paper; * = sole author; 
** = principal author; *** = joint author 
Table 2. Supporting documents 
Publication Status
*
 
Detection of cortical lesions is dependent on choice of slice thickness in 
patients with multiple sclerosis. Dolezal O, Dwyer MG, Horakova D, Havrdova 
E, Minagar A, Balachandran S, Bergsland N, Seidl Z, Vaneckova M, Fritz D, 
Krasensky J, Zivadinov R. Int Rev Neurobiol. 2007;79:475-89. 
RP*** 
Diffusion-weighted imaging predicts cognitive impairment in multiple 
sclerosis. Benedict RH, Bruce J, Dwyer MG, Weinstock-Guttman B, Tjoa C, 
Tavazzi E, Munschauer FE, Zivadinov R. Mult Scler. 2007 Jul;13(6):722-30. Epub 
2007 Mar 15. 
RP*** 
Comparison of three different methods for measurement of cervical cord 
atrophy in multiple sclerosis. Zivadinov R, Banas AC, Yella V, Abdelrahman N, 
Weinstock-Guttman B, Dwyer MG. AJNR Am J Neuroradiol. 2008 Feb;29(2):319-
25. Epub 2007 Nov 1. 
RP*** 
The place of conventional MRI and newly emerging MRI techniques in 
monitoring different aspects of treatment outcome. Zivadinov R, Stosic M, Cox 
JL, Ramasamy DP, Dwyer MG. J Neurol. 2008 Mar;255 Suppl 1:61-74. doi: 
10.1007/s00415-008-1009-1. Review. 
RP*** 
Use of perfusion- and diffusion-weighted imaging in differential diagnosis of 
acute and chronic ischemic stroke and multiple sclerosis. Zivadinov R, 
Bergsland N, Stosic M, Sharma J, Nussenbaum F, Durfee J, Hani N, Abdelrahman 
N, Jaisani Z, Minagar A, Hoque R, Munschauer FE 3rd, Dwyer MG. Neurol Res. 
2008 Oct;30(8):816-26. doi: 10.1179/174313208X341003. 
RP*** 
Gray matter atrophy and disability progression in patients with early 
relapsing-remitting multiple sclerosis: a 5-year longitudinal study. Horakova 
D, Dwyer MG, Havrdova E, Cox JL, Dolezal O, Bergsland N, Rimes B, Seidl Z, 
Vaneckova M, Zivadinov R. J Neurol Sci. 2009 Jul 15;282(1-2):112-9. doi: 
10.1016/j.jns.2008.12.005. Epub 2009 Jan 24. 
RP*** 
Voxel-wise magnetization transfer imaging study of effects of natalizumab 
and IFNβ-1a in multiple sclerosis. Zivadinov R, Dwyer MG, Hussein S, Carl E, 
Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, 
Bergsland N, Weinstock-Guttman B. Mult Scler. 2012 Aug;18(8):1125-34. doi: 
10.1177/1352458511433304. Epub 2011 Dec 22. 
RP*** 
Iron deposition on SWI-filtered phase in the subcortical deep gray matter of 
patients with clinically isolated syndrome may precede structure-specific 
atrophy. Hagemeier J, Weinstock-Guttman B, Bergsland N, Heininen-Brown M, 
Carl E, Kennedy C, Magnano C, Hojnacki D, Dwyer MG, Zivadinov R. AJNR Am J 
Neuroradiol. 2012 Sep;33(8):1596-601. doi: 10.3174/ajnr.A3030. Epub 2012 Mar 
29. 
RP*** 
Subcortical and cortical gray matter atrophy in a large sample of patients 
with clinically isolated syndrome and early relapsing-remitting multiple 
sclerosis. Bergsland N, Horakova D, Dwyer MG, Dolezal O, Seidl ZK, Vaneckova 
M, Krasensky J, Havrdova E, Zivadinov R. AJNR Am J Neuroradiol. 2012 
Sep;33(8):1573-8. doi: 10.3174/ajnr.A3086. Epub 2012 Apr 12. 
RP*** 
Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting 
Multiple Sclerosis over 2 Years: A Longitudinal Study. Zivadinov R, Tekwe C, 
Bergsland N, Dolezal O, Havrdova E, Krasensky J, Dwyer MG, Seidl Z, 
Ramasamy DP, Vaneckova M, Horakova D. Mult Scler Int. 2013;2013:231345. doi: 
10.1155/2013/231345. Epub 2013 Jan 10. 
RP*** 
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Publication Status
*
 
Gray matter SWI-filtered phase and atrophy are linked to disability in MS. 
Hagemeier J, Weinstock-Guttman B, Heininen-Brown M, Poloni GU, Bergsland N, 
Schirda C, Magnano CR, Kennedy C, Carl E, Dwyer MG, Minagar A, Zivadinov R. 
Front Biosci (Elite Ed). 2013 Jan 1;5:525-32. 
RP*** 
Improved longitudinal gray and white matter atrophy assessment via 
application of a 4-dimensional hidden Markov random field model. Dwyer 
MG, Bergsland NP, Zivadinov R. [Unpublished manuscript] 
N-P** 
*Status: P = available in the public domain; R = refereed journal paper; N-P = not yet 
available; * = sole author; ** = principal author; *** = joint author 
 
1.3 Statement of work 
This document summarizes, synthesizes, and critically evaluates published 
work of the author. This work involves the development and application of novel 
computational algorithms for quantitatively analysing magnetic resonance 
imaging (MRI) to better understand and characterize the pathology of multiple 
sclerosis (MS), its progression, and the response of patients to treatment. 
For the past decade, the author has served as senior computer scientist and 
technical director at the Buffalo Neuroimaging Analysis Center (BNAC, 
University at Buffalo, NY, USA), a multi-disciplinary institute specializing in 
quantitative MRI analysis. His role in the BNAC is one of independent 
conceptual leadership with regard to the application of computer science to MRI 
analysis techniques. 
In collaboration with Prof. Robert Zivadinov, whose expertise is in clinical 
neurology, the author has developed, adapted, and applied a range of MRI 
image analysis algorithms, designed to accurately quantify in vivo changes in 
the brain of MS patients, thus advancing both the work of BNAC and the 
discipline as a whole. Throughout his tenure, he has also served as the key 
technical planner in the design of analysis protocols for over 70 individual 
studies.  
The purpose of this submission is not to exhaustively catalogue this work, but 
rather to provide evidence supporting conferral of a degree of PhD by published 
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work. Therefore, the specific subset of papers selected is based on the 
cohesiveness of the work reported and the fact that it demonstrates substantial 
independent leadership and involvement by the author. While most of these 
papers relate to MS in one way or another, a paper on the assessment of stroke 
is also included, because the methodologies developed in that study laid 
important groundwork for subsequent investigations of MS patients. 
1.4 Justification for the work 
Because it is non-invasive, non-ionizing, and can distinguish with great 
accuracy pathological changes in soft tissue, MRI has become widely used in 
the diagnosis, management, and study of neurological conditions such as MS. 
Although it has already facilitated major clinical and scientific advances, it is 
nonetheless a relatively new technology, with the first commercial whole-body 
scanners only appearing in 1980 (Ai et al. 2012). While these early machines 
were primitive, over the subsequent decades rapid technological improvements 
have been made which allow MRI to quickly and accurately map many aspects 
of tissue at resolutions on the order of a cubic millimetre. Consequently, MRI is 
capable of harvesting a wealth of raw data from patients and delivering new 
insights into the nature of many neurological diseases.  
While advances in MRI physics have been rapid, they have not consistently 
translated into improved ability of clinicians and researchers to interpret the raw 
data into meaningful information. In practice, within a single one-hour scanning 
session, ten or more full conventional and/or non-conventional 3-dimensional 
tissue maps can be produced, each emphasizing different aspects of the local 
chemical environment and/or pathophysiology. Indeed, a single MRI scanning 
session may produce over a gigabyte of data comprising multiple intensity 
readings in millions of voxels (3D pixels). Without sophisticated quantitative 
tools to cope with this vast amount of information, many radiologists‘ only 
recourse is to make qualitative judgements or simple hand calculations. 
However, this approach is subjective and prone to operator error and 
misinterpretation (Drew et al. 2013). Furthermore, the use of qualitative 
assessment can mean that only a small proportion of the data collected is 
utilized, with much potentially useful information discarded. Consequently, 
quantitative methodologies have been developed in recent years that enable 
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the data to be collected and analysed more reproducibly and in much greater 
detail.  
By conferring the ability to synthesize data, elucidate subtle effects, and refine 
and standardize outcome measures, quantitative MRI image analysis holds 
great potential to lead advances in both basic science and clinical treatment. 
With its roots in signal processing, statistics, and pattern recognition, it has 
become a field in its own right (Dhawan 2011; Dougherty 2009), and has 
already seen many early successes. Nevertheless, it is a young field, with great 
potential for improvement and many unexplored frontiers.  
The aetiology and pathophysiology of MS is poorly understood, with the result 
that the full clinical relevance of MRI data collected may not be known. Although 
MS is known to be associated with many MRI factors, the clinico-radiological 
paradox – the fact that MRI findings do not correlate well with clinical outcome – 
remains troublesomely unresolved (Barkhof 1999; Barkhof 2002). 
Understanding the precise impact of therapy on brain atrophy and tissue 
integrity is complicated by factors like pseudoatrophy (Zivadinov, Reder, et al. 
2008) and measurement error, and the best way to deal with these remains an 
open question. Even seemingly straightforward issues like quantifying lesion 
burden remain fraught with difficulties. How does one distinguish between 
lesion and more subtle dirty-appearing white matter (WM)? How does one 
quantify pathology with extremely diffuse edges? Consequently, there is need to 
develop new, accurate techniques that can reliably quantify tissue integrity, 
lesion burden, and atrophy in greater detail, so that disease onset and 
progression can be better understood and therapeutic impact can be better 
assessed.  
In addition to the need for new analysis techniques, it is important to ensure 
consistency in the fast moving field of MRI.  For example, how does one deal 
with subjective decisions made by different MRI analysts, regarding the choice 
of regions of interest (ROI) to investigate? Furthermore, how does one ensure 
that increasing the power of the MRI machine (e.g. from 1.5T to 3T) does not 
completely invalidate cross-group comparisons? These and many other ‗softer‘ 
issues have not been sufficiently discussed. However, given that clinical and 
scientific findings are often based on the outcome of MRI image analysis, it is 
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important that consistency of analysis is maintained and that robust protocols 
are developed. 
1.5 Aims and objectives 
The overall aim of the work was to develop, adapt, or refine quantitative image 
analysis methodologies to improve both the precise characterization of MS 
pathology and progression and the assessment of therapeutic interventions. 
The specific objectives of the work were to: 
(i) Develop a new methodology for accurately quantifying 
volumetric loss in the optic nerves of MS patients. 
(ii) Develop an improved methodology for accurately quantifying 
grey matter (GM) atrophy in MS patients. 
(iii) Develop an improved methodology for assessing the 
heterogeneity of microstructural tissue damage in MS patients. 
(iv) Develop an improved methodology for accurately and reliably 
quantifying pathological intracranial features with diffuse 
boundaries on MRI images.  
(v) Develop a new methodology for accurately quantifying and 
localizing ongoing demyelination and remyelination in the whole 
brain of MS patients. 
(vi) Develop a standard methodology for quantifying iron deposition 
in specific structures in the brains of MS patients. 
(vii) Evaluate the extent to which increasing the field strength of the 
MRI machine influences the outcome of MS lesion analysis. 
(viii) Evaluate the extent to which operator variability regarding 
choice of ROI influences the quality of MRI lesion 
measurements in MS patients.  
8 
 
 
 
 
 
Chapter 2 – Background and context 
 
This chapter presents an overview of the background research underpinning the 
work of the author and his collaborators. This work is interdisciplinary in nature 
and overlaps between three key areas: MRI, MS, and image processing and 
analysis. Therefore, to provide context and to familiarize readers with these 
fields, a brief overview is provided below. For readers completely unfamiliar with 
these fields or desiring more information, Appendix D reviews each in further 
depth and provides additional key references. 
2.1 MRI 
MRI is a young but extremely versatile medical imaging modality. Through a 
combination of superconducting magnet, gradient-producing coils, and 
radiofrequency (RF) coils, it is capable of interrogating tissue protons to 
elucidate many details about their chemical environment (Haacke 1999). The 
technique is three-dimensional, non-invasive, and non-ionizing. Although more 
time consuming than computed tomography (CT) it can produce a unique array 
of contrasts, each of which can provide specific clinical or scientific information 
not otherwise obtainable (Fig 1). Classically, these contrasts included proton 
density (PD), T1, and T2, but many more have been discovered as well. Of 
particular note are diffusion (Le Bihan 2003), which can quantify the molecular 
motion of water, and magnetization transfer (Henkelman et al. 2001), which is 
particularly sensitive to macromolecules. 
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Figure 1: Conventional MRI sequences showing different tissue properties: FLAIR 
(left), proton density (center), and T2 (right). Images have been co-registered to show 
exactly the same slice, but each has a different contrast mechanism. 
 
Most neuroimaging MRI scanning sessions produce five to ten different three-
dimensional image volumes with resolutions on the order of one to five cubic 
millimetres per voxel. They are usually interpreted qualitatively by trained 
radiologists, but they can also be directly digitally transferred for more rigorous 
quantification.  
2.2 Multiple sclerosis 
Multiple sclerosis is a chronic, often debilitating disease of the central nervous 
system, thought to affect more than two million individuals worldwide (Rosati 
2001). It is the most common neurologically disabling disease in young adults, 
and currently has no known cure. It usually begins with a relapsing/remitting 
phase followed by later conversion to progressive deterioration, but other 
courses are possible and the effects vary widely between individuals (Poser et 
al. 1982). 
The hallmark pathology of MS is the presence of focal inflammatory 
demyelinating plaques (Fig 2) that disseminate in both time and space. These 
lesions can appear in many areas, and are common in periventricular, 
juxtacortical, infratentorial, and spinal regions (Polman and Reingold 2011). 
During the acute phase of their formation, there is usually evidence of blood-
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brain-barrier breakdown. Over time, many result in permanent gliosis and 
diminished or absent axonal conduction (Frohman et al. 2006).  
 
Figure 2: FLAIR image of a representative secondary progressive MS patient showing 
hallmark focal lesions, predominantly in the periventricular regions. Additionally, 
enlarged ventricles and thinning cortical gyri indicate brain atrophy. 
 
Since MS was identified by Jean-Martin Charcot in 1866, many disparate 
factors have been implicated in its aetiology and progression. Environmental 
studies have revealed associations with latitude, sunlight, infectious diseases 
(particularly Epstein-Barr), vitamin D intake, and smoking (Ascherio and Munger 
2007a; Ascherio and Munger 2007b). A genetic component is also implicated 
based on higher co-occurrence in twins (Willer et al. 2003), and genome-wide 
studies have identified specific candidate loci (Hafler et al. 2007; De Jager et al. 
2009). Immunology has provided many insights, including the role of CD4+ and 
CD8+ T cells, and B cells are currently receiving increased attention (Kasper 
and Shoemaker 2010). Histopathology has also shed much light, demonstrating 
widespread damage and neurodegeneration beyond simple demyelinating focal 
lesions (Trapp and Nave 2008) as well as the presence of substantial GM lesion 
burden (Geurts et al. 2009). However, despite significant progress in all these 
areas no single factor has been fully explanatory, and a comprehensive disease 
model remains elusive. 
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Although a cure has not been found, treatment options have expanded greatly, 
and have now gone beyond symptom management to actual slowing of disease 
progression. The most popular therapies are the beta interferons and glatiramer 
acetate, but others like natalizumab (Polman et al. 2006) and fingolimod 
(Kappos et al. 2010) have also proven valuable, and even more such as 
alemtuzamab (Coles et al. 2008) and ocrelizumab (Kappos et al. 2011) are on 
the horizon. None of these drugs are without side effects, though, and individual 
responses often vary. 
2.3 Medical image processing and analysis 
For much of its history, neurological MRI was mainly qualitative in nature, but 
more recently clinicians, MRI physicists, and researchers have begun to draw 
on the fields of statistics, image analysis and signal processing to develop new 
methodologies. However, medical images pose their own problems, and so 
adaptation of general algorithms developed in other fields to neurological MRI 
remains a major challenge. Nonetheless, substantial progress has been made. 
MRI is capable of producing a wealth of raw data, but the transition from this 
raw data to meaningful information is not always straightforward. A single MRI 
scanning session may produce multiple intensity readings for over nine million 
voxels (Fig 3). Consequently, a qualitative approach to MRI analysis is likely to 
result not only in diagnostic inconsistency, but also in much valuable data being 
discarded. Furthermore, even if it were possible to fully evaluate all of this data 
by eye, there would remain the difficult question of which pieces of information 
are clinically relevant and how they interrelate. Quantitative MRI image analysis 
can address both of these issues. By bringing modern medical image analysis 
techniques to bear, it is possible to process the massive raw datasets provided 
by MRI quickly and reliably. Because it can distil raw data into specific metrics, 
quantitative MRI can also help address questions of relative importance and 
interrelation by facilitating the use of statistical modelling and/or data mining 
techniques to correlate MRI findings with other meaningful clinical outcomes like 
physical disability and cognition. Such applications range from the relatively 
intuitive – e.g. the realization that lesion counts may not be as important or 
predictive as volumetric measurement in MS (Fisniku, Brex, et al. 2008) – to the 
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completely new and exciting, as in structural and functional connectomics 
(Bullmore and Bassett 2011).  
 
Figure 3: Visual overview of typical MRI data produced by a single, clinical scanning 
session. (N.B. Research protocols can comprise much more data.) 
 
To a reasonable first approximation, medical image analysis can be split up into 
pre-processing and processing stages. Pre-processing is concerned with such 
tasks as noise attenuation, artefact correction, and post-acquisition alignment. 
Removal of noise can be accomplished in many ways, from simple smoothing 
(Gonzalez and Woods 2008) to more complex methods like anisotropic diffusion 
(Black and Sapiro 1998). Artefact correction includes such techniques as bias 
field removal (Sled et al. 1998) and distortion correction (Andersson et al. 
2003). Post-acquisition alignment is particularly important, as it allows data from 
multiple contrast types, time-points, or individuals to be synthesized. 
Consequently, it is a relatively mature field with robust techniques for both co-
registration (linear, within-individual alignment) (Jenkinson and Smith 2001) and 
normalization (non-linear warping for inter-individual alignment) (Klein et al. 
2009). Furthermore, high-resolution, modern MRI atlases have been developed 
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that allow for the alignment of scans into a common space that facilitates 
collaboration between researchers and uniform understanding of scientific 
findings (Mazziotta et al. 2001). In general, pre-processing techniques take 
images as input and produce modified or refined images as output. 
Processing techniques are more challenging to summarize, as they are highly 
varied and application-dependent. They can be qualitative, also producing 
images as output, or quantitative, producing well-defined metrics as output. In 
either case, they can provide an important alternative or complement to 
qualitative radiological reads. General techniques include contouring, 
segmentation, and anatomical parcellation. Contouring, either automated or 
semi-automated, can be used to identify focal lesions, and has been 
substantially refined via the use of edge-finding techniques and iso-contours 
(Grimaud et al. 1996). Segmentation is usually fully automated, and involves the 
classification of individual voxels into tissue categories (e.g. GM, WM, CSF), 
sometimes including pathology (Van Leemput et al. 2001; Zhang et al. 2001; 
Ashburner and Friston 2005). Anatomical parcellation uses varying models and 
techniques to reliably extract specific structures such as deep GM nuclei or 
specific cortical gyri (Patenaude et al. 2011; Fischl 2012).  
In addition to general techniques, more contrast-specific processing algorithms 
have been developed, including diffusion-based fibre tracking (Ciccarelli et al. 
2008), magnetization transfer ratio-based macromolecular quantification (Filippi 
et al. 1998), and BOLD-based functional MRI analysis (Jezzard et al. 2002). 
These specific techniques continue to evolve in tandem with improvements and 
discoveries in MRI sequence development. 
 
2.4 MRI image analysis in MS – overview of the field 
Concurrent with and interwoven into advances in epidemiology, immunology, 
and histopathology, MRI has already played a dramatic role in MS, where it has 
both answered and generated many questions. Given the multifactorial nature 
of MS, it is in many ways an ideal target for quantitative MRI research since it 
can simultaneously provide information about so many different aspects of CNS 
tissue (Fig. 4). 
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Figure 4: MR imaging in MS has been used to elucidate many different aspects of the 
disease. Although there are many exceptions, most current techniques can be broadly 
categorized as measuring focal pathology, tissue atrophy, or "invisible" damage. 
 
Focal pathology (in the form of lesions) was the earliest recognized element of 
MS, and remains one of the most important clinical outcomes. From a clinical 
perspective, MRI sensitivity to lesions has substantially improved diagnostic 
criteria and differential diagnosis (Miller and Weinshenker 2008; Polman and 
Reingold 2011). In many clinics, it has also become a common standard of care 
to perform routine MRI to assess neurologically silent progression and assist in 
evaluating response to treatment. There has even been some evidence that 
lesions could be used as a primary endpoint in clinical trials (Sormani and 
Bruzzi 2013), but this has been debated (Rudick and Cutter 2013). From a 
research perspective, the spatial and temporal resolution achievable with MRI 
has led to a much better understanding of the formation, progression, and 
eventual fate of lesions (Ciccarelli et al. 1999). Also of particular interest, 
through the interplay of histopathology and MRI, chronic T1 hypointensities 
(―black holes‖) have been identified as an important subset of lesions that are 
more indicative of axonal loss and neurodegeneration than standard T2-
hyperintense lesions (van Walderveen et al. 1998). Remaining problems in this 
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area mainly stem from difficulty in standardizing lesions measures across 
scanners and operators (Grimaud et al. 1996; Zijdenbos et al. 2002), although 
novel correlative approaches still continue to shed light on the disease process 
(Gourraud et al. 2013) and the precise relationship between lesions and atrophy 
is still under investigation (Mühlau et al. 2013). 
Another aspect of MS that has been greatly illuminated by MRI is atrophy. 
Some patients show extensive atrophy late in the disease, and its precise role 
has been historically not well understood. With quantitative MRI analysis, it has 
become possible to more precisely characterize tissue atrophy and to reduce it 
to precise numerical quantities.  This has led to the understanding that MS is 
not simply a focal inflammatory disease, but also a neurodegenerative condition 
(Chard et al. 2002; Losseff et al. 1996; Miller et al. 2002; Simon et al. 1999). 
Typically, young healthy adults lose approximately 0.15% of their brain volume 
per year (Ge et al. 2002), whereas an annual loss of 1.5% or more has been 
observed in MS cohorts (Ge et al. 2000; Zivadinov et al. 2001). As such, 
assessment of atrophy is now increasingly becoming an important end-point in 
MS therapeutic trials  (Filippi et al. 2004; Filippi et al. 2001; Rudick et al. 2000). 
One notable finding has been that pathology in MS is markedly different 
between GM and WM (Geurts and Barkhof 2008), and this has led to increased 
interest in measuring their individual atrophy dynamics. Atrophy occurs at 
broadly different rates between the GM and WM (Ge et al. 2001; Sanfilipo et al. 
2006). GM volume appears to have a closer relationship with disability (Fisniku, 
Chard, et al. 2008) and cognitive impairment (Benedict et al. 2006; Sanfilipo et 
al. 2006; Riccitelli et al. 2011) than is the case with the WM, although both are 
clearly important (Bodini et al. 2009; Bodini, Cercignani, Khaleeli, et al. 2013; 
Papadopoulou et al. 2013), and less GM pathology is seen in benign MS 
(Calabrese et al. 2013). The ability to reliably and independently detect subtle 
GM and WM volumetric changes in vivo is therefore an issue of critical 
importance, with some arguing that atrophy should be ―upgraded‖ to a gold 
standard outcome measure in MS treatment (Rudick et al. 2013). However, 
despite the acceptance of atrophy as a key component of MS, its precise 
nature, cause(s), and mechanism(s) are still not fully understood. A number of 
possibilities have been discussed and explored, (Trapp and Nave 2008; 
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Zivadinov, Reder, et al. 2008) but further work is still needed to fully understand 
the phenomenon. 
Beyond lesions and atrophy, MRI has also been extensively used to investigate 
more subtle, ―occult‖ tissue changes in MS. For example, myelin is a critical 
target for both research and therapeutic intervention, and as MRI techniques 
have improved, there have been some promising approaches to achieve more 
myelin-sensitive imaging. Although no MRI marker  has been found to have high 
specificity, one technique, MTR (Berry et al. 1999), achieves good sensitivity by 
taking advantage of the fact that water bound to large macromolecules, 
particularly myelin, responds with resonant behaviour to a wider range of radio 
frequencies than free water. By comparing images with and without the 
additional application of an off-resonant pulse, the local concentration of 
macromolecules can be indirectly inferred. MTR has been used to successfully 
detect myelin changes in lesions (van Waesberghe et al. 1998; Brown et al. 
2012). MTR changes have also been observed in normal-appearing tissue 
(Filippi, Campi, et al. 1995; Bodini, Cercignani, Toosy, et al. 2013), but it is not 
clear whether these represent changes in myelin content or other processes 
such as axonal loss, since primary demyelination is not known to occur outside 
lesions. Similarly, diffusion imaging has also been used to evaluate the 
microstructure of tissue and to detect in vivo myelin changes (Ciccarelli et al. 
2003), and diffusion tractography has shown how connectivity changes can 
affect cognition (Bozzali et al. 2013). Beyond this, MS spectroscopy has also 
been used to investigate changes in specific metabolites in the CNS (Srinivasan 
et al. 2005; De Stefano et al. 2007; Ciccarelli et al. 2007), although its resolution 
remains relatively crude. More recently, interest in iron dynamics in MS have 
also been revived due to the emergence of new phase-sensitive MRI 
techniques (Deistung et al. 2013; Zheng et al. 2013). 
Although significant advances in MS image analysis have been made on all 
these fronts in recent years, there are still significant ‗holes‘ in the knowledge 
base. For example, precision in lesion measurements remains challenging, the 
early detection of atrophy is extremely difficult, and dynamic myelin changes are 
difficult to localize and quantify in vivo. From a broader perspective, and 
perhaps most importantly, the clinico-radiological paradox remains unresolved. 
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Consequently, there is need to develop new methodologies with which to better 
understand and interpret MRI data regarding MS. 
2.5 MRI image analysis in MS – statistical modelling 
Given these challenges, the author initiated a programme of work geared 
toward addressing them (see Chapter 3 for details). Although individual 
problems require individual solutions, in broad terms the author applied 
statistical modelling techniques to address many of the objectives outlined in 
section 1.5. Statistical modelling provides a rigorous and useful framework, and 
allowed the author to draw on much existing work. In particular, the concepts of 
regularization, robust statistics, and multiple comparison correction were 
utilized. In order to aid the reader, these concepts are briefly introduced here. 
As this is a summary and synthesis document, formal mathematical rigor will be 
avoided in the interest of providing a more intuitive, high-level overview.  
2.5.1 Models and regularization 
MRI researchers and clinicians are consistently faced with a trade-off between 
scanning time, noise, and spatial resolution. Since time is limited, these last two 
factors are almost always compromised to some degree, creating significant 
challenges for quantitative image analysis. In the absence of any information 
about the underlying system, these challenges would be overwhelming. 
Fortunately however, this is not the case, because nearly all real-world MRI 
images have some underlying structure to them that can be exploited. For 
example, neurological MRI images usually have a great deal of spatial 
consistency – although there are many transitions between tissue types, they 
are almost always at least contiguous. Perhaps surprisingly, even this simple 
observation can dramatically improve many quantification approaches. Of 
course, exploiting such information is not completely free, and one must be 
careful to balance a priori notions against actual observations. 
This balance is usually referred to as the bias/variance trade-off, and is a 
relatively mature field in mathematics and optimization theory (Hastie et al. 
2011). The abstract intuition described above is formalized in a number of more 
mathematically precise and rigorous ways in different applications, but most fall 
under the categories of regularization or model fitting. In the context of the 
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author‘s work, one of the most important and illustrative of these approaches is 
the hidden Markov random field (HMRF) model (Winkler 2003). 
At the core of this model is the Markov property, which roughly asserts that the 
probability of each state transition for a given system only depends on the 
current state, and not on any prior states. The Markov property is a significant 
over-simplification of the real world, but is often surprisingly tenable in many 
practical applications. For example, disparate areas like gambling, stock 
markets, and speech can all be modelled as Markovian processes. In the 
current context, the Markov property is also important from a spatial perspective 
rather than a temporal one, and the conventional Markov chain is generalized to 
the concept of a 2- or 3-dimensional Markov random field. In essence, taking 
the Markov assumption allows tissues on MRI to be modelled in such a way that 
only the direct neighbours matter in classifying or segmenting a given voxel. In 
turn, this allows for a direct calculation of how likely a given configuration is a 
priori. Finally, by combining this a priori spatial configuration information with 
observed voxel intensities, a maximum a posteriori (Bayesian) estimate can be 
created. The Markov random field approach was introduced for MRI tissue 
segmentation in (Held et al. 1997) and substantially refined by (Zhang et al. 
2001), who added the ―hidden‖ aspect to explicitly model the noise in image 
acquisition. 
Using HMRFs or other similar models, the ultimate balance between bias and 
variance can usually be reduced to a single, clear parameter choice. In theory, 
Bayesian approaches can be used to calculate the optimal value for this 
parameter to minimize the total actual expected error. In practice, though, this is 
difficult to determine analytically and so is often determined using empirical 
approaches like simulation, bagging, cross-validation, or L-curve modelling. 
2.5.2 Non-parametric statistics 
The study of non-parametric statistics is a very broad field, of which two 
particular elements are primarily relevant to the author‘s body of work: robust 
statistics and permutation testing. 
Robust statistics (Huber and Ronchetti 2009) provide a precise and rigorous 
means for estimation of distribution parameters in the face of substantial noise 
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or even minor bias. These are generally split into estimators of location and 
estimators of scale. Estimators of location are analogous to the conventional 
use of the mean, and can be as simple as trimmed mean or median and as 
complex as Huber or Hempel ψ-function based M-estimators. Estimators of 
scale are analogous to standard deviation, and can similarly range from familiar 
approaches like interquartile range and median absolute deviation to more 
unique approaches like Qn and Sn estimators. The Qn estimator is of particular 
interest, because it is efficient, does not depend on a location estimate, and is 
computationally feasible to calculate. It is essentially the median value of all the 
pairwise differences between all items in the set being studied. 
Permutation testing solves a different but related problem: how to assign formal 
significance values when the underlying distribution is not known. Conventional 
techniques like Student‘s t-test assume a known family of parameters 
underlying the null hypothesis, such that the probability of observing a given 
value by chance can be analytically determined. In contrast, permutation testing 
makes almost no assumptions about the nature of the underlying data, and 
determines the likelihood of observing a given value empirically from the data 
itself. For example, the equivalent of a t-test is performed by continually re-
assigning group labels, and determining in what percentage of random 
labellings the observed difference is more than in the true labelling. Permutation 
testing is not a new concept (Pitman 1937), but is very computationally 
intensive. The rise of cheap, powerful computers have therefore contributed to a 
marked rise in their use and applicability. Even today, though, permutation tests 
still usually only use a percentage of the total number possible combinations via 
Monte Carlo sampling. 
2.5.3 Multiple comparison correction 
In theory, performing statistical tests per voxel can provide unparalleled regional 
information that would otherwise be ―lost in the average‖. However, it also 
severely exacerbates the problem of multiple comparisons – there are millions 
of voxels in many MRI images. Conventional Bonferroni correction is also 
useless, resulting in highly over-conservative conclusions. The key to solving 
this problem is that meaningful results generally do not occur in single isolated 
voxels, but rather in clusters. This observation can be exploited to create more 
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appropriate and suitably powerful statistical tests. One of the early (and still 
widely used) approaches in this area is Gaussian random field (GRF) theory 
(Worsley et al. 1996). Like nearly all parametric statistical approaches, GRF 
theory makes certain assumptions about the data in exchange for power. 
However, these assumptions may not be valid for a given experiment, and are 
sometimes difficult to defend in novel research areas where data behaviour is 
not yet well understood. In particular, application of GRF theory generally 
requires a strong a priori hypothesis about the degree of tissue change that will 
be observed, in order to choose an appropriate cluster-forming threshold. 
Permutation testing is a more recent, non-parametric alternative to this that can 
provide more appropriate results while making minimal assumptions. With this 
approach, group labels are randomly permuted and values are calculated in 
order to build up an empirical null distribution. It has been used with great 
success to make statistical inferences in voxel-wise statistical mapping 
problems (Nichols and Holmes 2002). 
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Chapter 3 – The author’s contribution to the knowledge base 
 
This chapter presents an overview of the author‘s original work (as set out in his 
published papers) and his contribution to the field of MS research.  
3.1 Narrative framework 
In order to contextualize the author‘s work and to aid the reader in 
understanding the author‘s contribution to the knowledge base, a narrative 
framework (shown in Table 3) has been constructed, which describes in a 
cohesive manner the body of the work presented. For ease of reference, this 
framework groups the author‘s various papers into distinct sections, with each 
section dealing with related ‗contributions‘, which are mapped against the 
specific objectives identified in section 1.5.  
The overall goal of the author‘s work has been to advance the use of 
quantitative analysis of MRI images in order to better understand MS. Over the 
years in which the author has been working in this field, pursuit of this goal has 
led him to explore many avenues of research, with much of the work developing 
organically, rather than fitting any pre-planned scheme. However with 
retrospective reflection, it is clear that the body of work broadly fits into the three 
distinct, but related sub-areas (tissue atrophy; occult pathology; and focal 
pathology), outlined in Table 3. Taken together, these sub-areas highlight 
different aspects of MS pathology, and serve as a contextual framework for the 
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author‘s work. Prior to 2007, the author also published a number of preliminary 
studies associated with the quantification of tissue atrophy, which laid the 
foundation for later more sophisticated work. Because of the formative nature of 
this work, these preliminary studies are reported in a separate section in Table 
3.  
Table 3: Narrative framework of the author's published work 
Section Description 
Objectives 
met 
Relevant 
papers 
3.2 
Preliminary 
work 
This section presents an overview of the author‘s 
early work, which formed the basis of the later 
studies relating to tissue atrophy. 
N/A 1, 2, & 3 
3.3 Tissue 
atrophy 
Neurodegeneration, characterized by tissue atrophy, 
is a major component of MS disease progression, 
and is predictive of future disease course, disability, 
and cognitive outcome. As such, it is an important 
target of research and therapeutic development. 
Therefore, methods for its accurate quantification 
and tissue-specific assessment are highly important.  
This section presents an overview of the author‘s 
work relating to tissue atrophy. In particular, a new 
methodology for accurate optic nerve atrophy 
quantification is presented, together with a 
dramatically improved methodology (algorithm) for 
accurately quantifying GM atrophy in MS patients. 
(i) & (ii) 7 & 11 
3.4 Occult 
pathology 
The term ‗occult pathology‘ refers to pathologies that 
are beyond the range of ordinary knowledge and 
understanding.  Numerous investigations have 
demonstrated that the so-called ‗normal-appearing‘ 
tissue in MS is often damaged in subtle ways that 
are not immediately apparent on conventional MRI. 
These include diffuse white matter axonal injury, 
abnormal iron accrual, and cortical demyelination.  
This section presents an overview of the author‘s 
work relating to some of the occult pathologies 
associated with MS. In particular, an improved 
methodology is presented for quantifying 
pathological intracranial features with diffuse 
boundaries on MRI images, along with an improved 
methodology for assessing the heterogeneity of 
microstructural tissue damage in MS patients. Also 
presented is a new methodology for accurately 
quantifying ongoing demyelination and remyelination 
in the whole brain of MS patients. Finally, a standard 
methodology for quantifying iron deposition in 
specific structures in the brains of MS patients is 
(iii), (iv), (v) 
& (vi) 
4, 5, 6 & 
9 
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described.  
3.5 Focal 
pathology 
(error 
minimi-
zation) 
Although focal lesions are one of the best understood 
aspects of MS, their precise quantification remains 
difficult to standardize and reproduce. Errors can 
occur due to subjective decisions regarding the 
choice of regions of interest (ROI) to investigate. 
Also, the field strength of the MRI machine 
influences the outcome of lesion analysis. 
This section presents an overview of the author‘s 
work relating to error minimization and 
standardization in the assessment of focal lesions in 
MS. In particular, operator variability regarding 
choice of ROI is evaluated, as is the impact of 
increasing the field strength of the MRI machine on 
the outcome of lesion analysis. 
(vii) & (viii) 8 & 10 
 
3.2 Preliminary work 
Qualitative and quantitative MRI have provided much insight into atrophy in MS, 
but many key questions still remain. For example, precisely how and where 
does atrophy occur in MS?  What portion of atrophy is related to demyelination 
compared to actual loss of cell bodies? How does MS atrophy relate to clinical 
and cognitive outcomes? What is the best way to measure atrophy? Can 
atrophy be accurately detected over smaller time periods and/or in smaller 
groups of subjects in order to reduce the risk entailed in experimental clinical 
trials? 
In response to the above questions, the author undertook the work reported 
here.  Its beginnings can be traced to 2005, with some crude but important 
investigations into the basic nature of atrophy in MS and the factors affecting its 
measurement. In (Carone et al. 2006), a technique developed by (Dade et al. 
2004) was adapted to study region-specific atrophy in MS based on parcellation 
via familiar Talairach landmarks. This work confirmed that GM atrophy was 
present in MS, and that it was not necessarily uniform. However, the regions 
studied were relatively coarse and did not directly follow meaningful anatomical 
boundaries. In addition, by modern standards the GM/WM segmentation used 
was relatively imprecise.  At the same time, the author and his co-workers 
evaluated the impact of technical aspects like coregistration on a variety of brain 
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atrophy measurement techniques, and also underscored the significant difficulty 
of measuring brain changes in the short term (Fritz et al. 2006).  
Building on this early work, it was hypothesized that a simple and highly 
reproducible proxy for GM atrophy might be a valuable tool. Third ventricular 
width was proposed, based on its location between the left and right thalami, 
and the author and his co-workers were able to demonstrate that this measure 
explained significant variation in a number of important neuropsychological tests 
(Benedict et al. 2006). However, it was recognized that although third ventricular 
width may be important, it was not sufficient due to the heterogeneity of atrophy 
in MS.  The author and his co-workers therefore undertook additional work to 
develop reliable techniques for measuring other complementary aspects of 
atrophy, including that of the spinal cord (Zivadinov, Banas, et al. 2008). This 
preliminary work made it clear that studying small, well-defined structures could 
have substantial advantages, and additionally underscored the importance of 
precision in measurement. It also reiterated the need to better understand the 
actual nature of atrophy. 
3.3 Tissue atrophy 
3.3.1 Optic nerve and RNFL analysis 
Optic neuritis is one of the most common initial symptoms of MS (Sørensen et 
al. 1999), with nearly two thirds of patients suffering at least one acute episode 
(McDonald and Barnes 1992). Therefore, a natural extension of the early 
preliminary studies was to focus on the optic nerve and retina. The optic nerve 
and retina are important targets for better understanding the precise nature of 
tissue atrophy. Unlike other peripheral nerves, the optic nerve is actually a direct 
outgrowth of the diencephalon, deriving from embryonic retinal ganglion cells. 
As such, it is myelinated by oligodendrocytes rather than Schwann cells. 
Furthermore, the retinal nerve fibre layer (RNFL) is formed from the axons of 
the optic nerve, and is normally un-myelinated (Nolte 2008). Therefore, this two-
part system provides a unique opportunity to look at the same axons in two 
different places and states – one where they are myelinated and one where 
they are not – with very few additional confounds. Evaluating atrophy in both 
these structures at the same time thus has the potential to provide information 
about the specific atrophy related to axons as compared to demyelination. 
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Optical coherence tomography (OCT) already provides a fast, reliable, and non-
invasive way to quantify RNFL (Huang et al. 1991). However, there were not 
previously any reliable methods for optic nerve atrophy quantification beyond 
simple ROI-based techniques. Such techniques, while easily applied, are highly 
subject to error due to motion, slice angle, and scanner artefacts. To address 
these concerns, and to ensure that differences seen were due to real 
anatomical change and not just measurement error, a new approach was 
required. 
The author‘s solution to this problem was achieved via the creation of a shape-
based model fitting technique (Frohman et al. 2009). In this type of approach, a 
parameterized mathematical model is used to adjust an idealized shape such 
that it best matches acquired data. In most cases, the motivation for this is 
twofold. First, it dramatically reduces the number of parameters involved. In 
theory, fitting something like the optic nerve is highly multidimensional, with one 
parameter per voxel (i.e., partial volume of the structure in the voxel). By 
changing to a parametric shape representation, the challenge can be greatly 
reduced from potentially thousands of parameters to just a few. Second, by 
imposing an a priori morphology to the structure to be quantified, shape fitting 
serves as a form of regularization. Like other Bayesian approaches, this 
regularization can greatly assist with precision in the face of noise and artefacts. 
In this case, a circularly extruded cubic spline tube model was used, resulting in 
a total of only 9 parameters as a function of slice location (four for x, four for y, 
and one for diameter). At each point, a circular cross section was extruded with 
orientation determined by the spline‘s tangent vector and radius set by the 
equivalent model parameter. Given this model, fitting was performed in stages. 
First, cubic splines were fit to operator-identified points at the centre of the optic 
nerve on each slice. This fitting served both to characterize the path of the 
nerve and to smooth out any small errors in the manual point placement. In 
addition, deviation metrics were used to correct for movement between slices. 
After this, fitting of the diameter was performed by a brute force search through 
potential diameter values, by identifying the diameter value minimizing a 
gradient-matching cost function. 
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Overall, the approach was very successful, and atrophy measurement using 
this technique proved to be extremely reproducible. Specifically, it demonstrated 
a mean absolute scan-rescan error of only 0.06 mm (less than 5% of the nerve 
diameter). This precision is more impressive when considering the fact that it is 
only a little more than one tenth of the voxel width (0.49 mm). 
3.3.2 Precise longitudinal GM atrophy quantification 
Although atrophy has been suggested as a gold standard treatment outcome, 
others dispute this stance (Rudick et al. 2013). It is notable, though, that many 
of the counter-arguments involve technical difficulties associated with assessing 
tissue atrophy, rather than on atrophy per se. For example, pseudoatrophy 
(Zivadinov, Reder, et al. 2008) is an important phenomenon that results in 
paradoxically larger brain shrinkage with the initiation of therapy. Additionally, it 
is argued that atrophy is an end-stage effect that may not be apparent for years. 
Although these are important caveats, they are not insurmountable. Mounting 
evidence demonstrates that pseudoatrophy has less impact on GM than WM, 
so studying GM in particular may alleviate that problem. In sufficiently powered 
studies, volume changes are seen even in early CIS patients (Bergsland et al. 
2012; Henry et al. 2008) so it seems that the inability to see short-term atrophy 
is likely a result of imprecise measurement rather than an actual lack of tissue 
changes. In this case, it would be extremely important to improve the precision 
of existing GM atrophy measurement techniques. 
To address this issue, the author developed an improved algorithm for 
quantifying GM atrophy (Dwyer et al. 2012). Rather than work from the ground 
up, the widely accepted FAST tool (Zhang et al. 2001) and elements of SIENAX 
and SIENA (Smith et al. 2002) were taken as a starting point. Briefly, FAST 
works by applying a hidden Markov random field (HMRF) (Winkler 2003) 
expectation maximization (EM) model to classify tissue as GM, WM, or CSF 
and to estimate partial volumes within voxels. FAST‘s model is three-
dimensional, though – concerned only with the spatial neighbours of individual 
voxels. In the current work, this model was extended to be four-dimensional in 
order to account for temporal neighbours as well. Although dealt with more 
formally in the referenced paper, the intuitive motivation for this is relatively 
straightforward. In a real set of MRIs, many voxels have intensities midway 
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between the average intensities of tissue classes. In some cases, it‘s 
contextually clear what these voxels should be called (e.g. a single voxel 
completely surrounded by other voxels that are clearly WM), and in these cases 
FAST will classify them appropriately. In other cases (e.g. along borders), the 
correct classification is not clear at all, even to an expert human reader. In this 
case, the choice between tissues will be seemingly random, although FAST will 
attempt to be spatially consistent about that random classification. In this 
second case, a key difference between an intelligent human reader and FAST is 
that when reviewing a follow-up image, the human reader will be conservative 
and not consider the tissue to be changing unless it is clearly different in 
intensity. FAST will simply classify it as whichever intensity it is closest to, even 
if ‗closest‘ means it only changes in intensity by a fraction of a percent for voxels 
that were directly between classes. 
Initial testing with this improved model was very promising, and it was subjected 
to more rigorous validation techniques including scan-rescan error assessment, 
tests of agreement with controlled simulation, and ability to dichotomize 
clinically meaningful subject groups. In all cases, the model demonstrated 
significant improvement compared to standard SIENAX, including lower errors 
(absolute deviation), better correlation with whole-brain (non-tissue specific) 
measures, and significantly improved effect sizes (up to a 68% increase). 
3.4 Occult pathology 
As discussed previously, post-mortem and histopathological investigations have 
revealed abnormalities in MS tissue outside of traditional focal lesions (Allen et 
al. 2001). However, such investigations are usually only performed in terminal 
cases and so cannot shed much light on the more dynamic aspects of any 
occult pathologies that may be present. Because of this, it is unclear whether 
such diffuse tissue damage is a primary or secondary effect, and what role such 
damage plays in disease progression and outcome. 
3.4.1 Quantification of pathological features with diffuse boundaries 
Although the work described in this section was undertaken in the context of 
ischemic stroke, the algorithms developed by the author laid important 
groundwork for later work in MS patients. In acute stroke, a primary option for 
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treatment is thrombolytic therapy, but this therapy carries a high risk of 
intracranial bleeding. Therefore, before proceeding it is extremely important to 
know whether any tissue is actually still viable but at risk. Commonly, this has 
been evaluated on MRI via so-called ―perfusion-diffusion‖ mismatch, in which a 
diffusion abnormality is taken to represent unsalvageable tissue and a potential 
surrounding area of depressed but non-zero perfusion is taken to represent 
tissue that is salvageable but will become infarcted without intervention.  The 
salvageable tissue is called the ―ischemic penumbra‖. Because time is essential 
in stroke, an automatic approach for independently assessing volumes of infarct 
core and ischemic penumbra would be of great value, but available approaches 
based on simple standard deviation thresholding were highly susceptible to 
noise (Røhl et al. 2001; Takasawa et al. 2008). Also, unlike the infarcted core, 
the edges of the penumbra are often extremely diffuse; without a clear border, 
small variations in threshold can dramatically change volume. As such, 
assessment of the size of penumbra presents clinicians with a considerable 
challenge. 
In order to address this problem, the author developed a more noise-resistant 
and statistically rigorous approach. As discussed previously, hidden Markov 
random field (HMRF) modelling is a powerful tool providing just these 
capabilities in situations where observations are spatially correlated (i.e., where 
neighbouring voxels aren‘t truly independent). However, an HRMF model 
generally assumes corrupted viewing of categorically different underlying 
classes, and in this case the penumbra class was not well defined. To address 
this problem, a unique combination of M-estimators (Yuan and Bentler 1998), 
abnormality indexing, and HMRF was employed by the author (Dwyer et al. 
2008). An M-estimator was used to robustly calculate the intensity distribution 
characteristics of the infarct core and then a Mahalanobis distance metric was 
used to categorize the abnormality level of tissue. Finally, an HMRF model was 
used on this derived abnormality field to classify tissue. Intuitively, infarct core 
and contralateral normal tissue were made to ―compete‖ for ownership of the 
intermediate data, with tissue ultimately more similar to infarct being retained as 
penumbra.  
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Although this work appears at first sight to be unrelated to MS, it provided 
important experience and insight into the difficult problem of precisely 
quantifying tissue pathology that is both subtle and without sharply demarcated 
borders. More specifically, it also confirmed the applicability of M-estimators in 
assessing empirical image intensity distribution parameters, which was critical 
in solving the Monte Carlo MTR change problem discussed below. 
3.4.2 Microstructural tissue damage 
An early portion of the author‘s work aimed to employ diffusion MRI to better 
characterize microstructural tissue damage in normal appearing brain tissue. As 
mentioned briefly above, diffusion MRI uses specially tuned, temporally 
separated gradients of opposite polarity to specifically impact mobile nuclei (Le 
Bihan 2003). The effects of these gradients vary with the extent of molecular 
diffusion, and are processed to produce a quantitative map of the degree of 
diffusivity. In a healthy human brain, diffusivity is highly restricted by 
hydrophobic myelin sheaths, and so is considerably lower in WM than in GM. 
Loss of myelin (or cellular structure in general) reduces the barriers to molecular 
motion, and so increases diffusivity locally. 
In this work, diffusion metrics were evaluated by the author and his co-workers 
in the whole brain in addition to focal MS lesions (Tavazzi et al. 2007). Of 
particular note, the author introduced a novel metric: entropy. Whereas the 
conventional metric, mean apparent diffusivity (ADC), provides an estimate of 
the overall water diffusion in the tissue, entropy provides an estimate of the 
macroscopic variation in diffusivity levels. Although standard deviation is 
somewhat analogous, entropy is arguably more appropriate in this case. 
Although standard deviation and entropy are both minimized by all observed 
diffusivities being identical, they are maximized differently. Standard deviation is 
maximized by a bimodal distribution with peaks at the highest and lowest 
diffusion values. On the other hand, entropy is maximized by a completely 
uniform distribution where all possible diffusion values are equally observed in 
different tissue areas. Organized structure may well result in clusters of different 
diffusivity values, but disease is more likely to spread the distribution out. 
Confirming this theoretical concern, entropy was empirically demonstrated to be 
the best diffusion-based predictor of clinical outcome in the studied dataset. 
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Later work using the same technique demonstrated that entropy was also the 
best diffusion predictor of cognitive ability in MS (Benedict et al. 2007) and was 
also successfully used to show the microstructural effects of glatiramer acetate 
therapy (Zivadinov et al. 2011). 
3.4.3 In vivo mapping and quantification of dynamic myelin changes 
Remyelination is recognized as a competing process to destructive 
demyelination in MS (Bunge et al. 1961; Prineas and Connell 1979). So-called 
―shadow plaques‖ containing thin fibres have been shown to be partially 
remyelinated with a thinner sheath, and remyelinated axons have been found to 
have unique morphology (Prineas et al. 1993). However, nearly all of the 
information gleaned regarding this phenomenon is from cross-sectional data via 
post-mortem analysis or from animal models not perfectly equivalent to MS. 
Consequently, the timing and interplay of demyelinating and remyelinating 
processes in vivo in real MS patients was poorly understood, with the impact of 
therapy not yet precisely evaluated. Accurate in vivo detection of the active 
processes involved in demyelination and remyelination is difficult to achieve 
from a technical standpoint, primarily due to a lack of MRI specificity and very 
noisy images. Preliminary MTR-based work by (Chen et al. 2007) provided a 
threshold-based technique for detecting these changes, but it was restricted to 
areas within lesions. Because more subtle demyelination and remyelination 
may also occur outside of overt T2 lesions (e.g. in cortical lesions or potentially 
in pre- or peri-lesional WM), the author developed a novel, statistically rigorous 
method for quantifying them in the whole brain. 
The work drew on pre-existing techniques for cluster-based voxel-wise 
inference, but faced unique challenges – whereas VBM and fMRI methods rely 
on consistency in effect between subjects, myelination changes can occur in 
unique locations in different patients. This necessitates evaluation of voxel-wise 
changes on a per-subject basis, and makes standard permutation testing 
impossible.  It is feasible in this case to fall back to a GRF theoretic approach. 
However, given the potential for large areas of subtly altered myelin content, it is 
difficult to confidently choose a sufficiently meaningful cluster-forming threshold.  
During this time another group published a method called TFCE, for ―threshold-
free cluster enhancement‖ (Smith and Nichols 2009). TFCE provides a means 
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to elegantly sidestep the cluster-forming threshold drawback of GRF theory by 
nonlinearly modifying statistic images based on their local cluster support at 
multiple scales. Unfortunately, though, TFCE had no known closed form 
probability distribution function, and permutation testing could not be applied to 
a single subject. To resolve this, the author created a new technique to make 
inferences using a novel Monte Carlo simulation coupled with an M-estimator 
for variance estimation. This resulted in the ability to reliably estimate the null 
distribution for TFCE values in a single subject, and to thereby assign 
meaningful p-values on a multiple-comparison corrected, per-voxel basis. The 
final technique was validated in three separate ways, using scan-rescan, 
simulation, and application to real clinical data. 
3.4.4 Iron assessment 
Another potentially intriguing front in the exploration of not-conventionally-visible 
MS pathology and progression is iron detection and quantification. Iron toxicity 
has been implicated in other diseases including Parkinson‘s (Dexter et al. 1991) 
and Alzheimer‘s (Connor and Menzies 1992), and some early histopathological 
work indicated abnormal iron deposition in MS (Craelius et al. 1982; LeVine 
1997). Until recently, though, iron deposition was very difficult to image in vivo. 
Initial work with T2 shortening was promising, but was also limited by the 
relative non-specificity of T2 contrast (Bakshi et al. 2000). In the interim, new 
MRI techniques based on phase data have been proposed. Traditionally 
discarded in favour of magnitude data after Fourier reconstruction, phase data 
is exquisitely sensitive to magnetic field fluctuations imposed by the high 
susceptibility of iron. Unfortunately, it is plagued by serious and substantial 
artefacts including aliasing, background field contributions, and non-locality. 
However, modern processing approaches have been proposed that are capable 
of alleviating the majority of these artefacts and recovering much of the 
information available. These include the susceptibility-weighted imaging (SWI) 
technique (Haacke et al. 2004), and more recently QSM (Langkammer et al. 
2012). 
With these techniques, it has become possible to investigate iron deposition in 
MS with much more sensitivity than T2 shortening could provide (Haacke et al. 
2009). However, two concerns encouraged a careful, regional approach rather 
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than whole brain measures. First, even in healthy people the time-course of iron 
deposition is substantially different in different regions of the brain (Hallgren and 
Sourander 1958). Second, myelin changes can cause non-iron phase changes 
in WM (Yablonskiy et al. 2012). Therefore, the author initiated a programme of 
work to develop a GM specific means to quantify phase on a structure-by-
structure basis. 
To accomplish this, the author employed a novel combination of FSL‘s FIRST 
subcortical parcellation tool (Patenaude et al. 2011) and SWI (Zivadinov, 
Heininen-Brown, et al. 2012). FIRST uses shape models as described 
previously to reliably identify left and right thalamus, caudate, putamen, 
pallidum, hippocampus, nucleus accumbens, and amygdala on high-resolution 
T1-weighted images. By implementing a system for automatically running 
FIRST and then realigning and warping the FIRST-identified regions into SWI 
image space, it was possible to extract region-specific phase data for each 
region. In addition, normative data was collected from healthy controls and used 
to implement region-specific phase thresholds indicative of abnormal iron 
content. Using this, a novel measure of mean phase of abnormal phase voxels 
(MP-APV) was introduced. 
3.5 Focal pathology 
Although focal pathology is the most classically well-understood aspect of MS, it 
remains challenging to make full use of the amount of data that even 
conventional MRI produces. In particular, reproducibility has been relatively low 
despite improvements to MRI. Whereas atrophy reliability is within the 1% 
range, even optimistic reports of inter-rater lesion agreement have indicated 
variances of near 7% (Filippi, Horsfield, et al. 1995), and others have reported 
up to 20% (Jackson et al. 1993). In terms of actual voxel-level agreement, 
kappa values below 0.7 have been demonstrated between centres (Zijdenbos 
et al. 2002). Beyond this, variation between sequence parameters and a trend 
toward higher field scanners makes inter-site comparison difficult at best. 
Consequently, there is considerable scope for errors to occur, which might 
compromise otherwise sound technical advances. In attempt to better 
understand the sources of potential errors, the author and his co-workers 
undertook the following studies involving MS patients.  
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3.5.1 Operator impact on lesion measures 
Although automatic lesion detection has been, and continues to be an area of 
extensive active research, it has still not been widely adopted as a de facto 
method due to performance and precision issues (García-Lorenzo et al. 2013). 
As such, semi-automated operator-guided techniques have remained the gold 
standard – a situation that is likely to continue for the near future. Given that 
such semi-automatic classification still has a relatively high rate of error, 
improved precision is an important goal. To facilitate such improved precision, it 
is important to have meaningful measurements indicating the source(s) of 
imprecision. Otherwise, attempts to make improvements may easily be 
misdirected. Realizing this, the author and his co-workers initiated a programme 
of work aimed at providing an easily standardized and widely applicable means 
to separate out the key factors that contribute to error in lesion measurements.  
An appropriate measure or set of measures should have certain desirable 
characteristics, including ability to separate operator ability from lesion burden, 
ability to direct improvements toward specific areas, and resistance to 
―averaging out‖ of measurement noise. The commonly used similarity index and 
variants like Kappa or concordance provide the last characteristic, but not the 
first two. Therefore, the author and his co-workers developed a new set of 
measures termed detection error and outline error (Wack et al. 2012). A key 
aspect of these measures is that they operate in a tiered lesion-wise/voxel-wise 
manner rather than a purely voxel-wise manner, in contrast to many other 
methods.  Detection error reflects the lesion-wise probability of complete 
disagreement in marking a lesion, whereas outline error represents the degree 
of volume disagreement for lesions that were mutually agreed to exist. 
These measures were applied by the author to a real dataset calculated 
multiple times by different operators, and were found to be considerably more 
independent of overall scan lesion volume than similarity index. They also 
provided better feedback to individual operators to allow them to improve by 
focusing either on recognizing lesions or more accurately delineating them, as 
necessary. 
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3.5.2 Scanner impact on lesion measures 
Another major class of errors in lesion measures is scanner induced, either via 
hardware differences, changes in acquisition parameters, or both. From a 
hardware perspective, a major contributor to lesion salience is field strength. In 
particular, many research groups and clinical centres have moved from 1.5 tesla 
to 3 tesla scanners. Although the change in overall lesion volume was 
previously investigated (Sicotte et al. 2003), it was not clear if the impact of 
improved field strength was spatially homogenous. To address this question, the 
author and his colleagues adapted a recently introduced lesion probability 
mapping technique (Enzinger et al. 2006) to compare lesion maps calculated 
from paired images acquired on 1.5 and 3 tesla scanners (Di Perri et al. 2009). 
Specifically, the technique was modified to use pairwise statistics rather than 
group comparisons, and TFCE was substituted for the previous multi-resolution 
smoothing approach. The results agreed with previous work in showing a 
significantly higher lesion load at 3 tesla, but also revealed that lesions were 
more commonly differentially detected in specific regions – particularly the 
occipital horns of the lateral ventricles.  
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Chapter 4 – Discussion and conclusions 
 
4.1 Evaluation, limitations, and improvements 
The subset of the author‘s work described above produced a number of new 
algorithms and techniques that have already furthered the study of MS. In 
addition, many have continuing value and are still being used in ongoing 
studies. 
Two of the author‘s algorithms dealt with methods for better understanding the 
nature of tissue atrophy in MS, and included a new methodology for accurately 
quantifying volumetric loss in the optic nerves (Frohman et al. 2009) and an 
improved methodology for accurately quantifying GM atrophy (Dwyer et al. 
2012). This work was important in a number of ways. From a technical 
perspective, the optic nerve approach was an early and novel use of shape 
models in MRI of MS. Such shape models have continued to prove extremely 
useful in providing accurate and reliable semi-automated and automated 
analysis, and have notably been used in FMRIB‘s freely available and widely 
used FIRST software (Patenaude et al. 2011). From a scientific and clinical 
perspective, the optic nerve approach provided detailed data about the interplay 
between OCT, MRI, and visual outcome measures, and was important in 
elucidating the relative behaviour of optic nerve and RNFL. In particular, the low 
correlation of two highly precise measures – optic nerve diameter and RNFL 
thickness – was an important clue that volumetric changes are not entirely or 
necessarily even largely due to axonal loss. Along with the concurrent work of 
others, this helped to motivate the importance of studying WM and GM 
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separately. The improved method for quantifying GM atrophy is more practical, 
but equally important since it is capable of reducing the number of subjects 
required to demonstrate atrophy-reducing efficacy in clinical trials. This both 
helps to protect more patients from the risk inherent in trials, and also allows 
more funds to be diverted to continued exploration of other therapeutic 
avenues. In fact, the approach has already been used in a large study and 
demonstrated improved ability to discern treatment effects (Zivadinov, 
Bergsland, et al. 2013). Also, the technique can potentially detect changes 
earlier, which may help to address some of the concerns with atrophy as a gold 
standard discussed above. 
As with any work, both of these techniques could have been improved, and 
more future work is required to build on the foundations laid. In particular, it 
would be beneficial to study the relationship between RNFL thickness and optic 
nerve diameter with more statistical rigor, and in particular to evaluate more 
complex models to better understand all sources of variance. Also, although 
initial investigations indicated that the optic nerve diameter is relatively constant 
over the area studied, the bias/variance trade-off of adding a linearly varying 
diameter parameter to the model was not systematically evaluated. In a similar 
vein, the GM quantification approach uses an empirical regularization 
parameter that could benefit from more formal study – e.g. with L-curves or 
related methods. Additionally, the emergence of very precise cross-sectional 
techniques (Dahnke et al. 2013), more anatomically targeted techniques 
(Vrenken et al. 2013), and availability of higher-quality MRI images may 
eventually obviate the need for such regularization. 
Four more methods were developed by the author to better elucidate occult 
pathology: an improved methodology for accurately and reliably quantifying 
pathological intracranial features with diffuse boundaries (Dwyer et al. 2008), an 
improved methodology for assessing the heterogeneity of microstructural tissue 
damage (Tavazzi et al. 2007), a new methodology for accurately quantifying and 
localizing ongoing demyelination and remyelination in the whole brain (Dwyer et 
al. 2009), and a standard methodology for quantifying iron deposition in specific 
brain structures (Zivadinov, Heininen-Brown, et al. 2012). The first technique 
laid important groundwork for the others in addition to its direct benefit in acute 
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ischemic stroke. The method for measuring microstructural tissue damage was 
important at the time it was done, but has since been largely overtaken by 
diffusion tensor imaging (DTI) and tractography (Ciccarelli et al. 2008), which is 
capable of answering much more detailed questions and it is sensitive not only 
to the magnitude of diffusion but also to its directionality. However, the author‘s 
work did introduce a novel use of entropy that might still be worthwhile to apply 
to DTI-specific metrics.  
The voxel-wise myelination detection technique developed by the author was 
more directly applicable, and led to the ability to investigate demyelination and 
remyelination not just in the natural course of the disease, but also on the effect 
of therapies on MTR. In particular, it was applied to a cohort of patients treated 
with either interferon beta 1-a or natalizumab (Zivadinov, Dwyer, et al. 2012), 
the results of which strongly suggested that natalizumab may significantly 
promote remyelination compared to interferon beta 1-a. Work with this method 
is still ongoing, and it is hoped that it can continue to be improved in a number 
of ways. First, given its basis on MTR it is sensitive but not entirely specific to 
myelin, but may also include some sensitivity to other macromolecules and 
therefore result in some false positives. Although other investigators have 
provided convincing evidence that this concern is not overly large (Giacomini et 
al. 2009), it would clearly be better to more completely eliminate it. Since this 
work was completed, other investigators have continued to expand the 
capabilities of MRI to do just this by detecting and quantifying myelin more 
specifically. In particular, novel sequences have been proposed that address 
these specificity concerns with MTR while still retaining high sensitivity, 
including qMTI (Janve et al. 2013), which may be clinically feasible (Dortch et 
al. 2011; Stikov et al. 2011), mcDESPOT (Spader et al. 2013), and robust 
myelin water fraction (Kwon et al. 2013). Since the majority of work on the VW-
MTR technique described is related to statistical modelling, it is largely pulse-
sequence-agnostic. It would therefore almost certainly be instructive to apply 
similar methodology to these improved myelin-specific images. However, it is 
important to note that none of these new methods are themselves perfectly 
specific to myelin, and the development of such an MRI marker is still an open 
research goal. 
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The iron assessment approach was also directly applicable. Although intuitively 
somewhat convoluted, the MP-APV measure was empirically shown to be well 
correlated with other non-iron metrics, including disability. In another study, it 
was shown that MP-APV may indicate iron deposition preceding atrophy in 
clinically isolated syndrome (CIS) patients (Hagemeier et al. 2012). This finding 
has also been replicated by another study (Al-Radaideh et al. 2013). Although 
cross-sectional results must be interpreted with caution, this observation is 
particularly intriguing, because it supports the idea that iron may have a 
causative or modulatory role in MS rather than simply being the end-product of 
myelin debris. Clearly, longitudinal studies are needed to substantiate this 
suggestion, but this work shows that they are certainly warranted. Further 
improvements to the technique will also help provide a more complete picture. 
In particular, phase imaging, though very sensitive to iron, is not perfectly 
specific and is also plagued by many artefacts. Modern approaches like 
quantitative susceptibility mapping (Langkammer et al. 2012) may provide more 
accurate measurements, and are currently being investigated by the author and 
his colleagues. 
Finally, two methods were introduced by the author to study influences on 
calculating more conventional focal pathology, including a method for 
decomposing the sources of inter-rater disagreement in semi-automated lesion 
assessment (Wack et al. 2012) and a technique for comparing lesion visibility at 
different scanner strengths (Di Perri et al. 2009). Although it seems likely that in 
the longer-term future automated identification techniques will largely replace 
manual assessment of lesions, the decomposition work remains relevant. The 
slow progress of automated techniques demonstrates that an overly simplistic 
solution is unlikely, and the ability to better identify specific sources of error in a 
rigorous and quantitative manner can also help direct development of future 
classification algorithms just as it can aid in the training of human operators.  
The method for comparing lesions at different scanner strengths clearly 
demonstrated the incompatibility of direct comparison between measures and, 
like (Sicotte et al. 2003), indicated the importance of using field strength as a 
statistical covariate or otherwise controlling for it in multi-centre trials. 
Furthermore, it lent weight to the idea that hyperintensities observed at the 
39 
posterior horns may be a normal variant, although the matter is not settled. 
Additionally, the pair-wise spatial approach might also be used for other 
applications, including measuring coil- and software-related changes. 
4.2 Overall impact 
The author‘s work as described above has had a significant impact on the work 
of the BNAC and that of other researchers, both in terms of direct contributions 
to the knowledge base and also in the creation of new techniques for future 
research. 
Overall, the author‘s work has contributed to the understanding of atrophy and 
occult pathology associated with MS, and has highlighted some consistency 
issues associated with quantifying focal pathology. Within the BNAC, the 
techniques developed have been used in numerous studies in different disease 
subgroups (Benedict et al. 2007; Horakova et al. 2009; Zivadinov, Heininen-
Brown, et al. 2012; Zivadinov, Dwyer, et al. 2012; Hagemeier et al. 2012; 
Bergsland et al. 2012; Zivadinov, Tekwe, et al. 2013; Hagemeier et al. 2013). 
Outside of the BNAC, they have complemented the ongoing work of others in 
the field in investigating the precise MRI-observable impact and course of MS, 
and the author‘s relevant publications have garnered over 250 citations at the 
time of this writing. In particular, it is now clear that atrophy is a complex 
phenomenon differentially affecting tissue classes, and that subtle atrophy 
occurs very early in the disease (Bergsland et al. 2012; Horakova et al. 2009). 
Furthermore, it is clear that atrophy occurs at different rates and with different 
impact in different areas and specific structures, and that these changes have 
an important impact on cognition (Bergsland et al. 2012; Benedict et al. 2006). 
With regard to occult pathology, diffusion entropy has been linked specifically to 
cognitive deficits (Benedict et al. 2007). Additionally, the VW-MTR technique 
has provided a better understanding of the locations and heterogeneity of subtle 
demyelination, and has also shown clear cortical changes (Dwyer et al. 2009; 
Zivadinov, Dwyer, et al. 2012). The author‘s phase imaging work has also led to 
particularly interesting findings, including the observations that iron likely relates 
to disability and that its deposition may precede atrophy (Hagemeier et al. 
2012). Taken together, all of these findings seem to agree with the observations 
of others that the neurodegenerative component is not a removed, secondary 
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effect, but rather potentially a primary process (Stys et al. 2012). Finally, the 
author‘s work with focal pathology, although perhaps less scientifically exciting 
than the other work, has provided important information about precisely where 
1.5 and 3 tesla scanners differ in lesion sensitivity, and has also indicated how 
to better train operators for agreement. 
As a whole and alongside the complementary work of many other researchers, 
these various contributions provide guidance for future investigations in addition 
to their direct impact. With respect to atrophy, the author‘s work underscores the 
need for better understanding of the disparate mechanisms associated with this 
phenomenon, in order to separately quantify the contribution of fluid-based, 
axonal, and myelin-based tissue losses towards overall brain atrophy. For occult 
pathology, the work motivates further steps to elucidate the causes of non-focal 
pathology, and perhaps suggests the need for more appropriate animal models 
that include iron abnormalities and diffuse demyelination. Finally, for more 
conventional focal pathology, the work indicates that more needs to be done in 
terms of standardization, and future investigations might better investigate 
specific scan parameter-based impacts and the precise causes of operator 
disagreement in outlining lesions. 
Outside of contributions to the knowledge base and indications of future 
directions, the work has also more directly resulted in the production of a 
number of useful algorithms that are both inherently valuable and can also be 
relatively easily adapted or applied to new problems. These algorithms include 
a semi-automated parametric shape model, a 4-D HMRF model for longitudinal 
tissue segmentation, a system for statistically robust quantification of subtle 
tissue changes (demyelination and remyelination), a technique for reliable 
quantification of structure-specific phase (representative of iron), and a 
decomposition method for quantifying specific error contributions to lesion 
identification. The techniques for voxel-wise MTR analysis and for improved GM 
classification will undoubtedly prove useful to monitor short and long term brain 
changes in a continuing variety of disease subclasses and therapeutic 
investigations. Equally importantly, the advances in understanding of lesion 
measurements can provide for more precise lesion burden measures in near-
term clinical trials. 
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Finally, it seems even more clear that, as suggested previously (Zivadinov, 
Stosic, et al. 2008), a true understanding of MS is unlikely to come from any 
single modality or technique, but rather from the fusion of many into a single 
composite picture. This type of fusion is likely to require substantial statistical 
modelling work on large, standardized datasets containing information about 
many facets of the disease. Accurate, reliable quantitative techniques including 
those presented by the author are therefore vital precursors to the goal of 
completely overcoming the clinico-radiological paradox. 
4.3 Conclusions 
MS is a serious, debilitating disease that currently has no cure and whose 
precise etiology and evolution are still not fully understood. Despite this, it is 
clear that rapid progress is being made on a number of fronts, including a better 
understanding of the nature of the disease itself and a much more effective 
armamentarium of therapeutic options. Therefore, there is cause for some 
optimism that the future will continue to hold meaningful improvements for 
patients with MS. 
The author‘s work described in this document has served a critical part in 
furthering this goal, both by directly answering important questions and by 
providing tools to answer future questions. Like the underlying disease, the 
related activities were multi-factorial, and dealt individually with atrophy, occult 
pathology, and focal pathology. 
With reference to tissue atrophy, the author has demonstrated that it is possible 
to use quantitative techniques to precisely measure volumetric loss both in 
specific structures and in individual tissue compartments. In particular, optic 
nerve atrophy can be measured with a precision approaching one-tenth of a 
voxel, and overall GM atrophy can be assessed reliably with up to 50% fewer 
subjects than previously required. 
With reference to occult pathologies, the author has demonstrated that higher-
order statistical measures like entropy provide valuable additional information, 
and also that these pathologies can be meaningfully quantified even when their 
boundaries are relatively diffuse. Furthermore, the author has shown that the 
extent of demyelination and remyelination can be measured in vivo, and has 
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also provided a reliable means for reproducibly quantifying phase (iron) in the 
basal ganglia. 
Finally, with reference to focal pathologies, the author has demonstrated that 
there are multiple, separable sources of error, and has provided techniques that 
can be employed to disentangle their relative impacts. 
The work described here has taken over a decade of concerted effort, and has 
proceeded as a combination of top-down planning and bottom-up reaction to 
empirical findings. In total, it has resulted in the creation of eight new techniques 
and many related scientific findings. Taken together, these both directly pushed 
forward the current knowledge of MS and provided re-usable tools to answer 
future questions.  
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Description: In this work, the author both conceived and implemented the 
mathematical framework and algorithm for the 4-dimension HMRF model. In 
addition, he performed all the simulation and scan-rescan work. The addition of 
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shared between authors. 
Independent contribution(s): Study planning; conceptualization and 
implementation of novel 4D HMRF algorithm; creation of abstract and poster; 
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To substantiate these claims, a supporting document from Professor Robert 
Zivadinov, BNAC Director, is provided below. As the senior researcher for the 
centre, he was usually most responsible for oversight of proper authorship 
apportionment for these papers. In addition, he was either last or first author for 
many of them.  
Supporting statements from additional authors can be provided upon request.
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This appendix collects the supporting documents published by the author. In 
contrast to Appendix B, the full documents have not been included in order to 
save space. Instead, the first page including the abstract has been provided. 
Full documents are available upon request to the author or directly from the 
associated journals. However, the unpublished manuscript related to work 11 
has been reproduced in full.
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Appendix D – Additional background 
 
This appendix provides more in-depth background and further references for 
readers interested in more information about MRI, MS, and image processing. 
D.1 MRI 
Magnetic resonance imaging (MRI) of human subjects was first successfully 
performed in 1977, with the first commercial whole-body scanner created in 
1980 (Ai et al. 2012). In the three decades since, MRI has become an essential 
medical tool available in more than half of surveyed emergency hospitals in the 
US and UK (Ginde et al. 2008; Kane and Whiteley 2008).  
The unique advantages of MRI that have driven its widespread use, include the 
fact that it is tomographic, capable of relatively high resolution of the order of a 
cubic millimetre or better, and that it is almost completely non-invasive. Equally 
notable, is MRI‘s ability to acquire a wide variety of data. By controlling the 
magnetic environment and probing tissue protons with radio frequency (RF) 
pulses, MRI is able to elucidate many different aspects of the chemical 
environment of hydrogen atoms. 
At its most basic, MRI is made possible by the combination of three key 
components: a relatively large superconducting magnetic coil, a system for 
radio frequency (RF) transmission and detection, and a set of magnetic 
gradient-producing coils (Fig. D1).  
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Figure D1: Schematic image of the core components of an MRI machine. The 
superconducting magnet aligns water protons and provides  them with a characteristic 
frequency. The gradient coils allow for spatial encoding by varying the local magnetic 
field. The radiofrequency coils interact with the spinning protons to elicit and read 
electromagnetic signals. 
 
It is impossible to do justice to the complex interplay at the heart of MRI image 
creation and acquisition in such a short space, but the basic principles are as 
follows: 
1. Hydrogen nuclei (consisting of single protons) have a characteristic 
physical property called ―spin‖ which can be conceived of as analogous 
to the angular momentum of a spinning ball or top. This spin also has a 
definable axis and direction (clockwise vs. counter-clockwise). This can 
of course be represented mathematically by a single positive or negative 
vector, but we treat the two separately here for simplicity. For the most 
part, the spin axes of hydrogen nuclei in vivo are oriented randomly. 
2. When a subject is placed in the MRI scanner, these hydrogen nuclei also 
begin to precess around the main field (B0) axis in much the same way 
that a spinning top begins to ―wobble‖ around the axis of gravity – the 
spin axis itself rotates around the field axis. The rate of this precession, 
called the Larmor frequency, is also a well-defined function on the 
magnetic field strength (e.g., 42.58 MHz/Tesla for hydrogen nuclei). 
3. In addition, although the spin axes were original oriented randomly, they 
now begin to align more closely with the scanner, as this corresponds to 
a lower energy state. Note that in reality, only a very small excess of 
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protons align with instead of against the field, on the order of a few parts 
per million. This is also a more classical view of the system that ignores 
the more quantum-dynamical underlying principles. See (Haacke 1999) 
for a more detailed discussion. 
4. When these precessing hydrogen nuclei are exposed to RF energy at or 
near their Larmor frequency (called an excitation pulse), their precession 
becomes phased, and their spin axes are also tipped away from the main 
magnetic field. With many protons spinning in phase and tipped away 
from the main field, a rotating net magnetic moment is produced in a 
plane perpendicular to the main field. In turn, this rotating magnetic 
moment induces a fluctuating electrical field that can be detected and 
measured with properly positioned RF receive coils and careful 
amplification. 
5. Once ―energized‖ by an RF field, protons do not simple remain at their 
newly ―tipped‖ angle and stay in phase. Instead, they trade energy with 
their surroundings and with each other in such a way that they begin to 
―relax‖ back into alignment with the main field and also lose phase 
coherence with each other. The process of tipping back into alignment 
with the main field is called T1 relaxation, whereas the process of losing 
phase coherence is called T2 relaxation. Both occur simultaneously, with 
T2 often much faster than T1, and each dependent of various aspects of 
the local chemical environment. Because of this, the strength of the RF 
signal read out at from a particular portion of tissue any given time after 
the initial excitation pulse is largely governed by three factors: the overall 
number of hydrogen nuclei in the tissue (proton density, PD), the T1 
relaxation rate of the tissue, and the T2 relaxation rate of the tissue. For 
simplicity, the important distinction between T2* and T2 is overlooked 
here.  
6. Finally, recalling that protons are excitable only by RF pulses at or near 
their Larmor frequency, and that the Larmor frequency itself is dependent 
on the magnetic field, it is apparent that by varying the local magnetic 
field it is possible to ensure that only protons in one specific area will be 
excited. This is the job of gradient coils, which produce spatial variations 
in the otherwise homogeneous main magnetic field in order to excite 
single slices. Within a slice, carefully timed application of additional 
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gradient fields can code already-excited nuclei in each portion of tissue 
with a specific identifying frequency and phase. By exploiting the 
mathematics of the Fourier transform, a great deal of data can be 
acquired simultaneously in this manner. 
 
7. Through the process of image reconstruction, a 3-dimensional grid (or 
series of 2-dimensional grids) is built up, composed of individual 
elements called voxels, for ―volume elements‖ (analogous to pixels, but 
with depth as well as height and width). 
Despite their brevity, the above principles provide some basic intuition for how 
conventional sequences like T1-weighted, T2-weighted, and PD-weighted 
images are acquired. By adjusting gradient/RF strength and application times, 
many variants can be acquired with different emphasis on scanning time, signal 
to noise ratio, and resolution. However, much more creative uses are possible 
with specialized RF/gradient techniques. For example, precise application of 
opposite polarity gradients can have no net effect on stationary nuclei, but 
dramatically affect moving nuclei, leading to diffusion contrast (Le Bihan 2003). 
Similarly, a well-tuned frequency offset in the RF field can be used to only excite 
protons in certain tissues, resulting in the potential for magnetization transfer 
contrast (Henkelman et al. 2001).  
In practice, within a single one-hour scanning session, ten or more full 
conventional and/or non-conventional 3-dimensional tissue maps can be 
produced, each emphasizing a different aspect of the local chemical 
environment and/or sensitive to different pathology. For clinical routine imaging, 
they are generally read qualitatively by a trained radiologist in a suitable visual 
format. For quantitative analysis, they are transferred in a standard format 
called DICOM, which ensures standard recording formats for most relevant 
acquisition parameters.  
A more complete description of the physics of MRI is beyond the scope of this 
document, but the interested reader is referred to (Hornak 2011) for an informal 
but informative overview, or to (Bernstein et al. 2004; Haacke 1999) for more 
comprehensive and rigorous treatment of the subject.  
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D.2 Multiple sclerosis 
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous 
system (CNS), which is characterized by inflammation, demyelination, axonal 
loss, and gliosis (Fig. D2). It is thought to affect more than 2 million individuals 
worldwide (Rosati 2001), and is the most common neurological disease 
amongst young adults. It commonly strikes individuals in their 20‘s or 30‘s 
(Koch-Henriksen and Sørensen 2010), and is usually characterized by acute 
clinical relapses followed by significant periods of remission. Eventually, though, 
most cases later enter a more debilitating progressive phase. The effects of MS 
are almost exclusively confined to the central nervous system, and the disease 
has as its hallmark focal pathological plaques with extensive demyelination 
located in otherwise myelinated central WM. Symptoms vary dramatically 
depending on affected areas, and include sensory deficits, muscle weakness, 
loss of balance, bladder dysregulation, visual changes, and cognitive 
impairment (Poser et al. 1982). 
 
Figure D2: Heterogeneity of MS disease-related changes. In addition to the hallmark 
focal plaques, many other pathological and reparatory mechanisms occur both 
simultaneously and in series. The precise distribution, timing, and interaction between 
many of these processes is still imperfectly understood. 
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Although first identified by Jean-Martin Charcot in 1866 (Goetz et al. 1995), the 
aetiology of MS remains unknown. Indeed, over the 150 years since it was first 
discovered many disparate factors have been implicated. Environmental studies 
have revealed an association with latitude, with populations at higher latitudes 
being more susceptible (Simpson et al. 2011). Although there is evidence for an 
effect of sunlight exposure potentially mediated through vitamin D (Munger et al. 
2004), there are also substantial east-west variations that indicate other climate 
related factors may be at work (Ebers and Sadovnick 1993). Infectious diseases 
have also been implicated, and there is convincing evidence that Epstein-Barr 
virus may play a role (Ascherio and Munger 2007). Other factors like degree of 
outdoor work (Kampman et al. 2007) and smoking (Riise et al. 2003; Zivadinov 
and Weinstock-Guttman 2009; Manouchehrinia et al. 2013; Salzer et al. 2013) 
have shown significant correlations with MS risk and outcome. Also, diet has 
been suggested and often discounted, although it seems that serum vitamin D 
levels may play a meaningful role (Munger et al. 2004).  In addition to these 
environmental factors, there appears to be an important genetic component. MS 
co-occurrence in monozygotic twins is significantly more likely than in dizygotic 
twins or non-twin siblings (Willer et al. 2003). Additional studies with half-
siblings have made a compelling case for a genetic/epigenetic basis for MS 
(Ebers et al. 2004). Beyond this, DNA microarray techniques have made it 
possible to cast a wide net in searching for likely contributors to MS. A recent 
large, genome-wide study identified specific risk alleles, including those of 
interleukin (IL2 and IL7) and human leukocyte antigen (HLA-DR) genes (Hafler 
et al. 2007), and another pointed to CD6, IRF8 and TNFRSF1A SNP locales 
(De Jager et al. 2009). However, despite the encouraging insights gained 
through these various studies, no overall comprehensive model of the disease 
exists and much about MS remains unknown, perhaps due to the complexity of 
epigenetic effects (Huynh and Casaccia 2013). 
In recent years much of the research into MS has focused on the immunological 
aspects of the disease. There is overwhelming evidence that MS is associated 
with inflammatory markers in the CNS (Brück et al. 1995). As seems to be the 
case with most aspects of MS, the immune responses involved appear to be 
multifaceted. For some time, CD4+ helper T cells have been implicated, and are 
clearly involved in the disease (Viglietta and Baecher-Allan 2004). However, 
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many other cell types and immunomodulatory cascades are also involved in 
MS, including CD8+ T cells and CD56+ natural killer cells (Skulina and Schmidt 
2004; Takahashi et al. 2004). Some populations like CD4+ Th1 T cells seem to 
have a disease-promoting effect, whereas others like CD25+CD4+ T cells are 
regulatory and suppress the immune response (Kasper and Shoemaker 2010). 
Of particular recent interest is the potential role of B cells in MS etiology 
(Magliozzi et al. 2007), and their potential as a therapeutic target (Hauser and 
Waubant 2008). 
Histopathological work has also shed much light on the precise nature of MS. 
Perhaps most importantly, it has made increasingly clear the fact that MS 
involves considerably more tissue damage than the conventionally seen focal 
T2 lesions, as well as the fact that even within such lesions considerably more 
activity occurs than simple demyelination (Lassmann et al. 2007). It has also 
demonstrated extensive alterations in previously little-studied GM, and has 
informed better understanding of its more subtle lesions (Geurts et al. 2009; 
Filippi et al. 2013; Fischer et al. 2013). Meningeal inflammation has also been 
found (Choi et al. 2012), which may more directly influence GM pathology. 
Mechanisms of neurodegeneration beyond Wallerian degeneration have also 
been elucidated, including direct axonal transection (Trapp and Peterson 1998). 
Perhaps one of the most interesting recent findings from histopathology is an 
evaluation of newly formed MS lesions. Surprisingly, this showed extensive 
oligodendrocyte apoptosis and microglial activation but minimal lymphocyte or 
myelin macrophage presence, contrary to current disease models (Barnett and 
Prineas 2004). Follow-up study with more cases confirmed the absence of T or 
B cells and the presence of apoptotic oligodendrocytes in early expanding 
borders of MS lesions (Henderson et al. 2009). Further investigation 
demonstrated a role for oxidative stress in pre-inflammatory oligodendrocytes 
(Haider et al. 2011). These findings have led some to hypothesize that MS may 
not be an autoimmune disease, but rather a degenerative disease resulting in 
an immune component (Stys et al. 2012; Trapp and Nave 2008). Additional 
work has pointed to the importance of astrocytes in remyelination (Skripuletz et 
al. 2013), and has shown other factors that can inhibit (Stoffels et al. 2013) or 
promote (Yuen et al. 2013) it. Given all of this, it has become clear that MS is a 
multifactorial disease, and the ability to monitor all these aspects shown via 
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histopathology with in vivo MRI is an important goal (Filippi et al. 2012). 
Additionally, the simultaneous combination of histopathology and post-mortem 
MRI may drive further advancements (Kolasinski et al. 2012). 
Arguably one of the greatest recent changes for those afflicted with MS is the 
fact that clinical care has progressed from passive observation, symptom 
management, and palliative care to meaningful disease modifying treatments 
that can significantly slow MS progress. These include large classes of immune-
modifying agents such as the beta interferons (Jacobs and Cookfair 1996) and 
glatiramer acetate (Ford et al. 2006), as well as more modern approaches that 
limit lymphocyte movement or proliferation such as teriflunomide (O‘Connor and 
Wolinsky 2011), fingolimod (Kappos et al. 2010), and natalizumab (Polman et 
al. 2006).  
D.3 Medical image processing and analysis 
For the first 15 years or so of its existence neurological MRI analysis was 
largely qualitive in nature, with most quantitative elements restricted to relatively 
simple calculations or low-level reconstruction applications. However in the late 
1990s, clinicians and MRI physicists started to turn to the world of signal 
processing and statistics to develop new methodologies. Since then, 
neurological image analysis has become a sub-discipline in its own right 
(Dhawan 2011; Dougherty 2009); albeit an immature discipline that is 
developing. While medical imaging provides a unique set of challenges, it 
benefits from algorithms developed in other fields. Application and interpretation 
of these algorithms in a neurological context, however, remains major 
challenge. While the systems in other disciplines may be well understood, this is 
not the case with neurological disease, where much is unknown about the 
intracranial system. Consequently, techniques originally developed in other 
disciplines have to be tailored to MRI image analysis and validated against 
experimental data. 
From the earliest stages of tomographic medical imaging (CT), computational 
power and sophisticated algorithms were required to reconstruct images from 
raw data, and this is still the case today. Where CT used the inverse Radon 
transform and iterative reconstruction, MRI now makes extensive use of the fast 
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Fourier transform (FFT). In the past few decades, though, computing speeds 
and memory have expanded to allow for considerably more possibilities than 
mere reconstruction. Because of this, the field of image analysis has grown 
dramatically, and has made quantitative interpretation and/or transformation of 
images a viable alternative or complement to qualitative radiological reads.  
Arguably some of the most critical advances in the field have come from areas 
that are traditionally considered ―pre-processing‖. In particular, co-registration – 
the mutual alignment of scans from different image types, time points, or 
subjects – has substantially matured to the point where it is highly reliable, due 
to the work of many independent investigators (Ashburner et al. 1997; Friston et 
al. 1995; Jenkinson et al. 2002; Woods and Grafton 1998). Co-registration is 
generally considered to be a linear operation, which although it can perform 
excellently between a single individual‘s scans, is not able to precisely align 
anatomy between different subjects. This concern can however be addressed 
by non-linear image warping, or normalization, which goes beyond affine 
transforms to allow detailed anatomy-specific warping/morphing. Such 
normalization may make use of hundreds or thousands of parameters, and is an 
extremely difficult mathematical and computational problem. Despite the 
challenges, though, significant progress was made even more than a decade 
ago (Woods and Grafton 1998) and improvements are still consistently being 
made. For example, much work has gone into invertible, diffeomorphic 
normalization (Klein et al. 2009; Murphy et al. 2011). Taken together, the value 
of fast, reliable, and reproducible post-acquisition alignment and normalization 
is difficult to overstate. Without such tools, it would be extremely difficult or 
impossible to track subtle changes across time, to evaluate the multi-spectral 
MRI characteristics of single tissue locations, or to compare localized changes 
across subjects. 
With co-registration and normalization available, simultaneous progress has 
been made on the creation and standardization of neurological maps, such as 
the famous atlas of neurology produced by Talairach and Tourneaux (Talairach 
and Tournoux 1988). Although crude by modern standards, at the time this 
represented a great step forward. However, it was based on a single subject 
data, and it was not until much later that the ability to warp many subjects into a 
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common space in a highly detailed manner was possible. Only when this 
obstacle was overcome was it possible to create much more accurate and 
representative atlases (Grabner et al. 2006) and ICBM 452 non-linear atlases 
(Mazziotta et al. 2001). With the ability to create high-quality atlases came the 
ability to perform group-wise spatial analyses. While early work was based on 
―collapsing‖ subject data into single metrics, the ability to normalize subjects into 
a common space led to the ability to precisely evaluate differences in specific, 
small anatomical regions all the way down to the voxel level. Some of the key 
techniques in this area include voxel based morphometry (Ashburner and 
Friston 2000) and deformation-based mapping (Chung et al. 2001). These 
techniques have been the basis for many independent investigations into 
morphometric changes in a variety of diseases and in normal aging (Draganski 
et al. 2004; Honea and Crow 2005; Prinster et al. 2006; Thompson et al. 2003). 
At the same time, improvements in image processing algorithms have led to 
accurate, reproducible tissue segmentation and object extraction techniques. 
These allow for classification on a voxel-by-voxel basis into specific tissue 
compartments or for labeling of voxels as specific anatomical structures. 
Examples of segmentation techniques include EMS (Van Leemput et al. 2001), 
FAST (Zhang et al. 2001), and SPM unified segmentation (Ashburner and 
Friston 2005). Examples of object extraction tools include FIRST (Patenaude et 
al. 2011) and cortical parcellation in Freesurfer (Fischl 2012). Other advances 
have occurred in lower-level processing areas, including a variety of techniques 
for image enhancement and/or restoration. For example, non-linear smoothing 
has provided a ―best of both worlds‖ ability to diminish measurement noise 
without paying the classical price of lost spatial resolution (Black and Sapiro 
1998; Smith and Brady 1997). Other techniques have focused more on 
ameliorating MRI-specific artefacts, including techniques for intra-session 
motion correction (Jenkinson et al. 2002), eddy current correction (Bodammer 
and Kaufmann 2004), and susceptibility-induced distortion unwarping (Jezzard 
and Balaban 1995). Finally, a number of more sequence-specific techniques 
have also developed symbiotically with MRI physics, including DTI-based 
tractography (Ciccarelli et al. 2008), fMRI ICA (Calhoun et al. 2009) and network 
analysis (Bullmore and Sporns 2009).  
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